Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $86.8571.

Several research analysts have commented on ESTA shares. Mizuho lifted their price target on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Citigroup dropped their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Finally, Canaccord Genuity Group raised their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th.

Establishment Labs Price Performance

ESTA stock opened at $58.31 on Monday. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -33.51 and a beta of 1.08. The company has a 50-day moving average of $68.05 and a two-hundred day moving average of $62.89. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $83.31. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The business had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. During the same period in the previous year, the company posted ($1.19) earnings per share. The firm’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities research analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00. Following the sale, the director directly owned 1,220,004 shares of the company’s stock, valued at $73,297,840.32. This trade represents a 0.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.09% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

Several large investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of Establishment Labs during the 3rd quarter worth approximately $34,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs in the fourth quarter valued at $47,000. State of Wyoming acquired a new position in shares of Establishment Labs in the third quarter valued at $71,000. Osaic Holdings Inc. lifted its position in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the period. Finally, MV Capital Management Inc. bought a new position in Establishment Labs in the fourth quarter worth $146,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.